Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Neil Barth, Gregory Bortz, Dov Perlysky

Premium

Agendia has hired Neil Barth to be its chief medical officer. Barth has 35 years of experience as a physician and in genomic biomarker development, and he led a staff of 1,400 physicians at Hoag Hospital in Newport Beach, Calif.


Enzo Biochem's shareholders have re-elected Gregory Bortz and Dov Perlysky to serve on the company's board of directors for three-year terms.

Bortz is founder and managing partner of Creo Capital Partners and he previously was senior VP of the Investment Banking Division of Lehman Brothers. Perlysky has been a managing member of the private investment firm Nesher and a director of the mutual fund Engex, and he has served on the board of directors at Pharma-Bio Serv and Highlands Bancorp.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.